C.R. Bard (BCR) 96.18 0.00

C.R. Bard, Inc.
(BCR) 96.18 0.00

Last Trade:	95.67	Day Range:	95.67 - 95.67
Trade Time:	04:02PM	52wk Range:	80.80 - 113.84
Prev. Close:	95.67	Market Cap:	8.21B
Open:	0.00	Div Yield:	0.78
Volume:	0	PE:	260
EPS:	3.69

The Latest On BCR

Notable Call Options Activity in C. R. Bard 2/10/12 3:12pm

Jefferies & Company Raises PT on CR Bard from $94 to $104 2/1/12 1:28pm

Citigroup Raises PT on CR Bard to $95 2/1/12 8:55am

UPDATE: Jefferies Increases C.R. Bard's PT from $94 to $104 2/1/12 8:34am

Piper Jaffray Concludes C.R. Bard's FY12 Estimates Remain Largely Unchanged Following Solid 4Q11 2/1/12 8:31am

Morgan Stanley Reiterates Equal-Weight on CR Bard 2/1/12 7:19am

Jefferies Raises PT on CR Bard to $104 2/1/12 6:39am

Top Performing Health Care Stocks in January 2/1/12 6:32am

Morgan Stanley Maintains Equal-Weight on CR Bard 12/21/11 10:04am

Bank of America Reiterates Neutral, $88 Target on CR Bard 12/21/11 9:52am

Morgan Keegan Lowers PT on CR Bard to $97 12/21/11 8:11am

UPDATE: J.P. Morgan Lowers Price Target on C.R. Bard to $92 12/21/11 8:10am

Notable Call Options Activity in C. R. Bard 2/10/12

Jefferies & Company Raises PT on CR Bard from $94 to $104 2/1/12

Citigroup Raises PT on CR Bard to $95 2/1/12

UPDATE: Jefferies Increases C.R. Bard's PT from $94 to $104 2/1/12

Piper Jaffray Concludes C.R. Bard's FY12 Estimates Remain Largely Unchanged Following Solid 4Q11 2/1/12

Morgan Stanley Reiterates Equal-Weight on CR Bard 2/1/12

Jefferies Raises PT on CR Bard to $104 2/1/12

Top Performing Health Care Stocks in January 2/1/12

Morgan Stanley Maintains Equal-Weight on CR Bard 12/21/11

Bank of America Reiterates Neutral, $88 Target on CR Bard 12/21/11

Morgan Keegan Lowers PT on CR Bard to $97 12/21/11

UPDATE: J.P. Morgan Lowers Price Target on C.R. Bard to $92 12/21/11

Top Performing Health Care Stocks in January 2/1/12

Earnings Preview: Becton, Dickinson & Company's EPS, Revenue Expected to Rise 10/28/11

Earnings Preview: Analysts Expect Boston Scientific's Revenue, Earnings to Dip 10/19/11

Earnings Preview: Baxter International's EPS, Revenue Expected to Rise 10/17/11

Edwards Lifesciences Earnings Preview: Analysts Expect Rising Revenue, Falling EPS 10/14/11

St. Jude Medical Earnings Preview: Analysts Expect Higher EPS, Revenue 10/14/11

Earnings Preview: Becton, Dickinson and Company EPS, Revenue Expected to Rise from Previous Quarter 7/28/11

Boston Scientific Earnings Preview: Analysts Expect Rising Revenue, Falling EPS Over Previous Quarter 7/25/11

St. Jude Medical Earnings Preview: Analyts Expect Higher Earnings, Revenue from Prior Quarter 7/15/11

Earnings Preview For Becton, Dickinson And Company (BDX, BAX, BCR) 4/25/11

A Peek Into The Market Before The Trading Starts 9/27/10

BCR: Steady Second-Quarter Results, Outlook Improving 7/23/10

Jefferies & Company Raises PT on CR Bard from $94 to $104 2/1/12

Citigroup Raises PT on CR Bard to $95 2/1/12

UPDATE: Jefferies Increases C.R. Bard's PT from $94 to $104 2/1/12

Piper Jaffray Concludes C.R. Bard's FY12 Estimates Remain Largely Unchanged Following Solid 4Q11 2/1/12

Morgan Stanley Reiterates Equal-Weight on CR Bard 2/1/12

Jefferies Raises PT on CR Bard to $104 2/1/12

Morgan Stanley Maintains Equal-Weight on CR Bard 12/21/11

Bank of America Reiterates Neutral, $88 Target on CR Bard 12/21/11

Morgan Keegan Lowers PT on CR Bard to $97 12/21/11

UPDATE: J.P. Morgan Lowers Price Target on C.R. Bard to $92 12/21/11

Citigroup Lowers PT on CR Bard to $84 12/21/11

Piper Jaffray Lowers PT on CR Bard to $86 12/21/11

Trade BCR
NOW!

Partner Headlines

Ask Top Guru Donald Yacktman Your Investing Question 2/12/12

Bard Bearish Signs 2/9/12

Ask Top Mutual Fund Manager Donald Yacktman Your Investing Question 2/7/12

Earnings Scorecard: Covidien - Analyst Blog 2/7/12

AngioDynamics to Buy Navilyst - Analyst Blog 2/2/12

Bard Tops in 4Q, Charges Crimp Net - Analyst Blog 2/1/12

10 Best 'Dividend Aristocrats' for 2012 2/1/12

Covidien's Solitaire Ok'd for Trial - Analyst Blog 1/31/12

Earnings Preview: C.R. Bard - Analyst Blog 1/30/12

Weekly Top Insider Sells: MSFT, INTC, BCR, MAR 1/30/12

AngioDynamics Cuts View on Recall - Analyst Blog 1/27/12

Earnings Preview: Covidien - Analyst Blog 1/25/12

Press Releases

Bard Announces Fourth Quarter Results 1/31/12 Business Wire Story

Bard to Host Earnings Conference Call on January 31, 2012 1/24/12 Business Wire Story

BUMI Launches Cloud Disaster Recovery Solution for Downtime-Intolerant Businesses 1/23/12 PRWeb Story

Bard Acquires Lutonix, Inc. 12/20/11 Business Wire Story

Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765 12/8/11 Newswire Story

Bard to Host December 2011 Investor Conference 11/3/11 Business Wire Story

Research and Markets: Value Investing & Investing Strategies Report 2011 11/2/11 Business Wire Story

Fitch Affirms Banco de Costa Rica's IDR at 'BB+' 8/30/11 Business Wire Story

Bard Announces Third Quarter Results 8/30/11 Business Wire Story

Bard to Host Earnings Conference Call on October 25, 2011 8/30/11 Business Wire Story

Bard Announces Agreement to Acquire Medivance, Inc. 8/30/11 Business Wire Story

Get the latest BCR stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for C.R. Bard, Inc. stock price.

C.R. Bard, Inc. by YCharts

C.R. Bard (BCR) 96.18 0.00

Quotes

Analysis

Twitter

Ownership

Earnings

The Latest On BCR

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social